Consistent with our findings, others have recently shown that venetoclax exhibits inhibitory activity toward the electron transport chain (ETC) independent of its intended target BCL-2, and this activity may contribute to the synergistic effect of venetoclax and ETC inhibitors in patients with hematological neoplasms [48–50]. The gene discussed is BCL2; the disease is hematopoietic and lymphoid system neoplasm.